Actively Recruiting
Bearing nsPVA Embolization for Uterine Artery Embolization (BETTER-UAE)
Led by Merit Medical Systems, Inc. · Updated on 2026-04-01
100
Participants Needed
4
Research Sites
118 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a prospective, multicenter, observational, post-market clinical follow-up study in subjects treated with Bearing nsPVA Embolization Particles for uterine fibroid embolization. Data collection will include safety and performance outcome relating to the use of Bearing nsPVA, through 6 months.
CONDITIONS
Official Title
Bearing nsPVA Embolization for Uterine Artery Embolization (BETTER-UAE)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult women 7 18 years old at the time of enrollment.
- Subject has symptomatic uterine fibroid(s), suitable to embolization.
- Subject provides written informed consent.
You will not qualify if you...
- Subject is pregnant.
- Subject has suspected pelvic inflammatory disease or any other pelvic infection.
- Subject has any malignancy of the pelvic region, such as endometrial neoplasia.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Astra Vascular/Astra Vein Treatment Center
Brooklyn, New York, United States, 11234
Actively Recruiting
2
The Wesley Hospital
Brisbane, Australia
Actively Recruiting
3
Alfred Health
Sydney, Australia
Actively Recruiting
4
Royal Gwent Hospital (Aneurin Bevan UHB)
Newport, United Kingdom
Actively Recruiting
Research Team
M
Molly Ryan
CONTACT
V
Vicky Brunk
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here